Novartis | NOVN - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 64.53B 5.59B 2026-03
Alcon AG USD 4.65B 491M 2026-06
Almirall EUR 303.77M 21.04M 2026-06
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
Autolus Therapeutics Ltd USD 277.27M 7.07M 2026-03
Bayer EUR 31.16B 480M 2026-06
Biogen USD 7.29B 1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Fresenius EUR 9.55B 1.24B 2026-06
Fresenius Medical Care EUR 5.82B 83.04M 2026-06
Genmab DKK 4.96B 28M 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
GRIFOLS EUR 7.17B 1.91B 2026-06
Hikma Pharmaceutical USD 1.49B 692M 2025-12
J&J USD 37.34B 183M 2026-06
Lakefront Biotherapeutics EUR 4.77M 78K 2026-06
Lonza CHF 3.88B 323M 2025-12
Merck EUR 11.21B 406M 2026-06
Merck USD 51.08B 4.41B 2026-06
Novartis USD 37.49B 42M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Novo Nordisk DKK 121.79B 2.62B 2026-06
Orion EUR 103.4M 7.2M 2026-06
Pfizer USD 60.5B 70M 2026-06
Philips EUR 6.32B 575M 2026-06
Recordati EUR 1.69B 67.09M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sanofi EUR 14.65B 806M 2026-06
UCB EUR 2.18B 634M 2025-12